tudybubblegumwadchum, it is sweet. ISIS was going for $42 a share about two months ago. It is going for almost $62 per share now. vicl was going for 44 cents a share and it is going for 44 cents a share now. Much, much more pain for the chums in 2016. Your ego is going to get you as will your jealousy. When is the next vicl move? You chums stated it would be in Nov. That is almost gone chum. t
SRPT slows the disease and their drug does have a very clean safety profile. It should get approved. BMRN was stupid to buy the company in the first place IMO. t
Capital F! Don't feel sorry for those kbio shorts at all. They would have redeployed the money and gone after other biotechs? KBIO should change its name to Kibosh Biotech. t
Tudywadchum, no one is jealous of vicl. A good way to find out would be for you and the chums to leave the board for a while and monitor and see if anyone even talks about vicl. It is only you chums that really have an interest in it. More pain coming your way from ignorance tudywadchum. BTW you might want to change your name to bubblegumwad. t
Your argument is sound. To me though I think these CART-1 inhibitor companies are way over priced and driven by hype. If these CA drugs from RNN could come through, even one for one strong indication it will have been worth the wait to me. As far as price competitiveness I think they wouldn't have a problem either compared to some of these really hyped bios. I would very much like to talk someone directly related to the company...that is their real weakness in regards to their shareholders. t
Your price target is right, but timing is off DPM. If you look at Akcea alone it has huge value. Their ApoC III inhibitor has the potential to treat 6K patients in the US and EU for two separate indications. If they are able to get the proper pricing for an orphan drug this drug should bring in over $1 billion per year. The second drug in the Akcea portfolio that will treat LpA(a) should be eligible for 10 to 30K patients again without an outcomes study needed for approval. That drug could potentially bring in over $450 million. I'm not factoring in the third drug in Akcea, the PKK inhibitor. ISIS is going for one, maybe two other orphan drug indications for this drug not including the HAE indication. If ISIS can bring in over $1.1 billion after taxes and expenses profit that is about $9 per share for the Akcea entity alone not including the PKK inhibitor. With a P/E of 30 that gets them a tenth of the way to your noted target goal. t
Another lie, I feel embarrasses for you chums when you lie like that. I don't even know what ILIU is, but you don't know the signicance of BK either. I guess being to snoopy and jealous is going to cost you. t
Most important for vicl is the are going to add another letter soon, a Q. t
Chum, you are living in the past and too dumb to see the future. Moreover it is good you have naive bliss about vicl's status of going over board ship to the pink sheets. t
A risk to be sure but if it hits $6 in two years that will be over 12 times your money on your investment. From what I've seen a risk I am willing to take and to be patient for. t
chumwiththeteeth, I'd be embarrassed to show my teeth with a four price share from vicl. That is where the jealous comes in. I guess it is human nature heh chum? t
The drug from ISIS Pharm has too many advantages and not nearly the side-effects with close to the potency of the competitor. Their partner GSK is really raising awareness and they have pharm reps in over 100 countries already. t
Listened to the CC tonight. A lot of the info was the same but there is a continued evolution in regards to the company's plan and some new info. Some of the newer info include:
1)Supinoxin continues to look good in treating triple negative breast CA. This is regarded as the worst type of breast CA save for maybe one or two others.
2)The toxic dosing amount still has NOT been reached.
3)Because of number two they have changed the dosing for the drug recently.
4)Rx-3117 also has had a change in dosing recently due to its not having had a toxic dose being reached.
5)The max dosing for Archexin has been reached. It is 250mg/m2/day. The low dose by itself at 125mg/m2/day has shown good tumor suppression.
6)The most important thing brought in the Q and A.....and I very much agree with this and it shows the wall street mentality of piling on to what seems like huge dream but they don't think about ultimate costs. Someone ask the CEO about threats from the PD-1 inhibitors and the PD-L1 inhibitors. He noted that they were generally effective in only 40% of the cases and as soon as someone is taken off of the meds the immune system changes that revert back have a very negative effect on you immune system and you get an almost self-attacking self situation.
7)He noted the financing was done recently as there was a fear of the window for that opportunity of closing. t
It looks like ISIS is going to be entering into the Crispr space. Their RNA technology looks to be able to be integrated into the Crispr format and do a better job than what is out there by the scRNA getting in to do the job and getting out leaving less room/time for off-target effects. This company will truly be a monster biotech within three years. t
Leptin relates to prolonged cardiovascular recovery after acute stress in Africans: the SABPA study
Nutrition, Metabolism & Cardiovascular Diseases, 11/16/2015
Pieterse C, et al.
The authors compared how cardiovascular reactivity and recovery relate to leptin in African (n=200) and Caucasian teachers. In Africans, higher circulating leptin levels associated with prolonged cardiovascular recovery after exposure to stress which could explain their increased vulnerability to hypertension development.
drugchum, you are really showing your stupidity in not knowing or wanting to admit there is an ongoing trial in babies for ISIS very safe drug that has not had ONE side-effect in babies in over two years. f
I don't think they will let the full article go through. I hope you get the main points I've noted. t